TWI374141B - Spiro-oxindole compounds and their uses as therapeutic agents - Google Patents

Info

Publication number

TWI374141B

TWI374141B TW095112903A TW95112903A TWI374141B TW I374141 B TWI374141 B TW I374141B TW 095112903 A TW095112903 A TW 095112903A TW 95112903 A TW95112903 A TW 95112903A TW I374141 B TWI374141 B TW I374141B

Authority

TW

Taiwan

Prior art keywords

group

benzodioxanthene

oxaspiro

snail

aryl

Prior art date

2005-04-11

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 title claims description 15
• 229940124597 therapeutic agent Drugs 0.000 title description 3
• 125000003118 aryl group Chemical group 0.000 claims description 397
• 125000001072 heteroaryl group Chemical group 0.000 claims description 373
• 125000000623 heterocyclic group Chemical group 0.000 claims description 351
• 241000237858 Gastropoda Species 0.000 claims description 343
• 125000000217 alkyl group Chemical group 0.000 claims description 316
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 284
• -1 dentate Chemical group 0.000 claims description 247
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 246
• 229910052739 hydrogen Inorganic materials 0.000 claims description 199
• 239000001257 hydrogen Substances 0.000 claims description 198
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 197
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 162
• 125000003342 alkenyl group Chemical group 0.000 claims description 160
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 151
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 148
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 138
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 132
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 128
• 150000002576 ketones Chemical class 0.000 claims description 120
• 150000001875 compounds Chemical class 0.000 claims description 114
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 114
• 125000000304 alkynyl group Chemical group 0.000 claims description 112
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 104
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 98
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 82
• 229910052757 nitrogen Inorganic materials 0.000 claims description 78
• 125000001424 substituent group Chemical group 0.000 claims description 74
• 125000003545 alkoxy group Chemical group 0.000 claims description 73
• 125000001188 haloalkyl group Chemical group 0.000 claims description 71
• 239000004202 carbamide Substances 0.000 claims description 64
• 208000002193 Pain Diseases 0.000 claims description 62
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 61
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 57
• 125000005843 halogen group Chemical group 0.000 claims description 57
• 125000005605 benzo group Chemical group 0.000 claims description 56
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 51
• 230000036407 pain Effects 0.000 claims description 51
• 229910052760 oxygen Inorganic materials 0.000 claims description 36
• 239000001301 oxygen Substances 0.000 claims description 36
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 34
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 31
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 28
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 27
• 201000010099 disease Diseases 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 26
• 125000002947 alkylene group Chemical group 0.000 claims description 25
• 238000011282 treatment Methods 0.000 claims description 25
• 208000024891 symptom Diseases 0.000 claims description 24
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
• 108010052164 Sodium Channels Proteins 0.000 claims description 22
• 102000018674 Sodium Channels Human genes 0.000 claims description 22
• 125000005842 heteroatom Chemical group 0.000 claims description 21
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
• KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims description 18
• 229910052799 carbon Inorganic materials 0.000 claims description 18
• 239000002253 acid Substances 0.000 claims description 17
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 16
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 16
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 16
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 15
• 125000004429 atom Chemical group 0.000 claims description 14
• 125000000468 ketone group Chemical group 0.000 claims description 14
• 150000002923 oximes Chemical class 0.000 claims description 14
• 241000124008 Mammalia Species 0.000 claims description 13
• 150000001412 amines Chemical class 0.000 claims description 13
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 13
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 12
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 12
• 125000000524 functional group Chemical group 0.000 claims description 12
• 208000004296 neuralgia Diseases 0.000 claims description 12
• 125000004122 cyclic group Chemical group 0.000 claims description 11
• 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 11
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 10
• 239000005711 Benzoic acid Substances 0.000 claims description 10
• 235000010233 benzoic acid Nutrition 0.000 claims description 10
• 239000007789 gas Substances 0.000 claims description 10
• 125000002346 iodo group Chemical group I* 0.000 claims description 10
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 9
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 9
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
• 229930194542 Keto Natural products 0.000 claims description 8
• 241001465754 Metazoa Species 0.000 claims description 8
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 150000001336 alkenes Chemical class 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 239000000203 mixture Substances 0.000 claims description 8
• 125000005429 oxyalkyl group Chemical group 0.000 claims description 8
• 150000003254 radicals Chemical group 0.000 claims description 8
• 239000010948 rhodium Substances 0.000 claims description 8
• 229910052707 ruthenium Inorganic materials 0.000 claims description 8
• 208000011580 syndromic disease Diseases 0.000 claims description 8
• 208000000094 Chronic Pain Diseases 0.000 claims description 7
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 7
• 229910052736 halogen Inorganic materials 0.000 claims description 7
• 150000002367 halogens Chemical class 0.000 claims description 7
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
• 229910000831 Steel Inorganic materials 0.000 claims description 6
• 229910052786 argon Inorganic materials 0.000 claims description 6
• 239000010949 copper Substances 0.000 claims description 6
• 125000000262 haloalkenyl group Chemical group 0.000 claims description 6
• 239000010959 steel Substances 0.000 claims description 6
• 239000000126 substance Substances 0.000 claims description 6
• 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 5
• 206010016654 Fibrosis Diseases 0.000 claims description 5
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
• 230000004761 fibrosis Effects 0.000 claims description 5
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
• 201000001119 neuropathy Diseases 0.000 claims description 5
• 230000007823 neuropathy Effects 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 230000033764 rhythmic process Effects 0.000 claims description 5
• 239000011734 sodium Substances 0.000 claims description 5
• 206010003119 arrhythmia Diseases 0.000 claims description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
• 230000001419 dependent effect Effects 0.000 claims description 4
• 230000004907 flux Effects 0.000 claims description 4
• 125000002541 furyl group Chemical group 0.000 claims description 4
• 208000014674 injury Diseases 0.000 claims description 4
• 150000002500 ions Chemical class 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 125000004076 pyridyl group Chemical group 0.000 claims description 4
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
• 239000003053 toxin Substances 0.000 claims description 4
• 231100000765 toxin Toxicity 0.000 claims description 4
• 239000002023 wood Substances 0.000 claims description 4
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 claims description 3
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
• 206010061218 Inflammation Diseases 0.000 claims description 3
• 206010065390 Inflammatory pain Diseases 0.000 claims description 3
• 208000028389 Nerve injury Diseases 0.000 claims description 3
• 206010038743 Restlessness Diseases 0.000 claims description 3
• 239000005864 Sulphur Substances 0.000 claims description 3
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
• 125000002837 carbocyclic group Chemical group 0.000 claims description 3
• 229910052802 copper Inorganic materials 0.000 claims description 3
• 150000001924 cycloalkanes Chemical class 0.000 claims description 3
• 230000006378 damage Effects 0.000 claims description 3
• 210000000232 gallbladder Anatomy 0.000 claims description 3
• 229910052737 gold Inorganic materials 0.000 claims description 3
• 239000010931 gold Substances 0.000 claims description 3
• 230000004054 inflammatory process Effects 0.000 claims description 3
• 230000008764 nerve damage Effects 0.000 claims description 3
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 3
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
• 208000019865 paroxysmal extreme pain disease Diseases 0.000 claims description 3
• 229910052703 rhodium Inorganic materials 0.000 claims description 3
• 150000003573 thiols Chemical class 0.000 claims description 3
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 208000020925 Bipolar disease Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical group C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 claims description 2
• 208000001640 Fibromyalgia Diseases 0.000 claims description 2
• 206010020844 Hyperthermia malignant Diseases 0.000 claims description 2
• 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims description 2
• 206010061533 Myotonia Diseases 0.000 claims description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
• 208000012075 Paroxysmal dystonia Diseases 0.000 claims description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 2
• 206010057040 Temperature intolerance Diseases 0.000 claims description 2
• 208000027418 Wounds and injury Diseases 0.000 claims description 2
• 150000001408 amides Chemical class 0.000 claims description 2
• 230000006793 arrhythmia Effects 0.000 claims description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
• 239000004305 biphenyl Substances 0.000 claims description 2
• 125000001246 bromo group Chemical group Br* 0.000 claims description 2
• 238000002512 chemotherapy Methods 0.000 claims description 2
• 229960001231 choline Drugs 0.000 claims description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
• 208000010118 dystonia Diseases 0.000 claims description 2
• 230000008543 heat sensitivity Effects 0.000 claims description 2
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 2
• 208000003532 hypothyroidism Diseases 0.000 claims description 2
• 230000002989 hypothyroidism Effects 0.000 claims description 2
• 230000001788 irregular Effects 0.000 claims description 2
• 230000000622 irritating effect Effects 0.000 claims description 2
• 201000007004 malignant hyperthermia Diseases 0.000 claims description 2
• 230000004112 neuroprotection Effects 0.000 claims description 2
• 201000008482 osteoarthritis Diseases 0.000 claims description 2
• 210000000578 peripheral nerve Anatomy 0.000 claims description 2
• 230000002085 persistent effect Effects 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
• 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 369
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 165
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 75
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 70
• 125000003003 spiro group Chemical group 0.000 claims 69
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 40
• 125000001041 indolyl group Chemical group 0.000 claims 34
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 29
• BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 23
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 21
• XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims 18
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 17
• OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 claims 16
• 229940067157 phenylhydrazine Drugs 0.000 claims 15
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 14
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 12
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims 12
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 9
• 229910021653 sulphate ion Inorganic materials 0.000 claims 9
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 8
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 8
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 7
• GZVHEAJQGPRDLQ-UHFFFAOYSA-N 6-phenyl-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C=CC=CC=2)=N1 GZVHEAJQGPRDLQ-UHFFFAOYSA-N 0.000 claims 7
• 206010011224 Cough Diseases 0.000 claims 7
• 235000007586 terpenes Nutrition 0.000 claims 7
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 6
• LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 6
• JWXYVIFJGFUTHL-UHFFFAOYSA-N 1,2-benzodioxol-3-one Chemical compound C1=CC=C2C(=O)OOC2=C1 JWXYVIFJGFUTHL-UHFFFAOYSA-N 0.000 claims 5
• QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 5
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 5
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 5
• 150000003505 terpenes Chemical class 0.000 claims 5
• 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
• YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims 4
• 229960005164 acesulfame Drugs 0.000 claims 4
• 229940037003 alum Drugs 0.000 claims 4
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 4
• 150000003857 carboxamides Chemical class 0.000 claims 4
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 4
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 4
• 210000003462 vein Anatomy 0.000 claims 4
• WPPHMBKSJVDIFZ-UHFFFAOYSA-N 3H-1,2-benzodioxole Chemical compound C1=CC=C2COOC2=C1 WPPHMBKSJVDIFZ-UHFFFAOYSA-N 0.000 claims 3
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 3
• OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
• 238000004519 manufacturing process Methods 0.000 claims 3
• 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 3
• UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 claims 3
• 230000002485 urinary effect Effects 0.000 claims 3
• PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims 2
• 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 2
• RNOVGJWJVRESAA-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)phenol Chemical group OC1=CC=C(F)C=C1C(F)(F)F RNOVGJWJVRESAA-UHFFFAOYSA-N 0.000 claims 2
• LLHWSBXZXJXVPL-UHFFFAOYSA-N 6-(2-methylphenyl)-1,3,5-triazine-2,4-diamine Chemical compound CC1=CC=CC=C1C1=NC(N)=NC(N)=N1 LLHWSBXZXJXVPL-UHFFFAOYSA-N 0.000 claims 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
• 206010019233 Headaches Diseases 0.000 claims 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
• XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
• 241000239226 Scorpiones Species 0.000 claims 2
• ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 2
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
• 210000000078 claw Anatomy 0.000 claims 2
• ILLHQJIJCRNRCJ-UHFFFAOYSA-N dec-1-yne Chemical compound CCCCCCCCC#C ILLHQJIJCRNRCJ-UHFFFAOYSA-N 0.000 claims 2
• BXNKCKFDLBMOTA-UHFFFAOYSA-N dioxol-3-one Chemical compound O=C1C=COO1 BXNKCKFDLBMOTA-UHFFFAOYSA-N 0.000 claims 2
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
• 235000013399 edible fruits Nutrition 0.000 claims 2
• KPYKFQNTASVHIG-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CC2=C=C[CH]N21 KPYKFQNTASVHIG-UHFFFAOYSA-N 0.000 claims 2
• 230000001939 inductive effect Effects 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
• 229930182817 methionine Natural products 0.000 claims 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
• AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical compound N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 claims 2
• RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 claims 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
• 239000000052 vinegar Substances 0.000 claims 2
• 235000021419 vinegar Nutrition 0.000 claims 2
• IGJRPICXFFLHNU-UHFFFAOYSA-L zinc;1,3-benzoxazol-2-olate;s-(dimethylcarbamoylsulfanyl) n,n-dimethylcarbamothioate;1,2,3,4,5,6-hexachlorobenzene;1,2,3,4,5,6-hexachlorocyclohexane Chemical compound [Zn+2].C1=CC=C2OC([O-])=NC2=C1.C1=CC=C2OC([O-])=NC2=C1.CN(C)C(=O)SSC(=O)N(C)C.ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl.ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IGJRPICXFFLHNU-UHFFFAOYSA-L 0.000 claims 2
• ABBMQADJUMXTAJ-UHFFFAOYSA-N (4-phenoxyphenyl)urea Chemical compound C1=CC(NC(=O)N)=CC=C1OC1=CC=CC=C1 ABBMQADJUMXTAJ-UHFFFAOYSA-N 0.000 claims 1
• AWCLKERIODTIBX-UHFFFAOYSA-N 1,3-oxazol-2-yl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=NC=CO1 AWCLKERIODTIBX-UHFFFAOYSA-N 0.000 claims 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
• HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 claims 1
• HIZVCIIORGCREW-UHFFFAOYSA-N 1,4-dioxene Chemical compound C1COC=CO1 HIZVCIIORGCREW-UHFFFAOYSA-N 0.000 claims 1
• GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims 1
• HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims 1
• BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
• 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims 1
• ANZYSVVUFUNMDA-UHFFFAOYSA-N 2-(2-fluorophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1F ANZYSVVUFUNMDA-UHFFFAOYSA-N 0.000 claims 1
• 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
• JDWWQTXSCOQPGB-UHFFFAOYSA-N 2-(3H-oxadiazol-2-yl)benzamide Chemical compound O1N(NC=C1)C1=C(C(=O)N)C=CC=C1 JDWWQTXSCOQPGB-UHFFFAOYSA-N 0.000 claims 1
• XUCBRNYDOZLKJX-UHFFFAOYSA-N 2-(trifluoromethyl)anthracene Chemical compound C1=CC=CC2=CC3=CC(C(F)(F)F)=CC=C3C=C21 XUCBRNYDOZLKJX-UHFFFAOYSA-N 0.000 claims 1
• QBAYIBZITZBSFO-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(F)(F)F QBAYIBZITZBSFO-UHFFFAOYSA-N 0.000 claims 1
• JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
• ZPRQXVPYQGBZON-UHFFFAOYSA-N 2-bromo-1h-indole Chemical compound C1=CC=C2NC(Br)=CC2=C1 ZPRQXVPYQGBZON-UHFFFAOYSA-N 0.000 claims 1
• 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
• GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 claims 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
• AJEUJXWLOADTKA-UHFFFAOYSA-N 2-piperidin-1-ylpyridine Chemical compound C1CCCCN1C1=CC=CC=N1 AJEUJXWLOADTKA-UHFFFAOYSA-N 0.000 claims 1
• FMQXTGYSIGNCPG-UHFFFAOYSA-N 2-pyrazol-1-ylbenzamide Chemical compound NC(=O)C1=CC=CC=C1N1N=CC=C1 FMQXTGYSIGNCPG-UHFFFAOYSA-N 0.000 claims 1
• DAWJJMYZJQJLPZ-UHFFFAOYSA-N 2-sulfanylprop-2-enoic acid Chemical compound OC(=O)C(S)=C DAWJJMYZJQJLPZ-UHFFFAOYSA-N 0.000 claims 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
• FKYMBTZSWQBPSW-UHFFFAOYSA-N 3,5-dimethyl-2,6-bis(3-methylbutyl)furo[3,2-f][1]benzofuran Chemical compound C1=C2C(C)=C(CCC(C)C)OC2=CC2=C1C(C)=C(CCC(C)C)O2 FKYMBTZSWQBPSW-UHFFFAOYSA-N 0.000 claims 1
• DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 claims 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 claims 1
• AHFINSWGYAZBOZ-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC(Cl)=CC=C1C=O AHFINSWGYAZBOZ-UHFFFAOYSA-N 0.000 claims 1
• BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 claims 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
• TWSIYGATPWEKBK-UHFFFAOYSA-N 4h-1,3-benzodioxine Chemical compound C1=CC=C2OCOCC2=C1 TWSIYGATPWEKBK-UHFFFAOYSA-N 0.000 claims 1
• IPEMCIBPDYCJLO-UHFFFAOYSA-N 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-n-(2,4,6-trimethoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1NC(=O)C(O1)=CC=C1CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IPEMCIBPDYCJLO-UHFFFAOYSA-N 0.000 claims 1
• YJRDHMUPONVWTE-UHFFFAOYSA-N 5-methoxy-2-(4-phenoxyanilino)benzoic acid Chemical compound OC(=O)C1=CC(OC)=CC=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 YJRDHMUPONVWTE-UHFFFAOYSA-N 0.000 claims 1
• FRQPHGSNRQEKOX-UHFFFAOYSA-N 6h-benzo[c][1,2]benzoxazine Chemical compound C1=CC=C2NOC3=CC=CC=C3C2=C1 FRQPHGSNRQEKOX-UHFFFAOYSA-N 0.000 claims 1
• IGGWMORAIJLDLU-UHFFFAOYSA-N 7,8-diazabicyclo[4.2.0]octa-1,3,5,7-tetraene Chemical compound C1=CC=C2N=NC2=C1 IGGWMORAIJLDLU-UHFFFAOYSA-N 0.000 claims 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 208000002874 Acne Vulgaris Diseases 0.000 claims 1
• 208000019901 Anxiety disease Diseases 0.000 claims 1
• 240000002900 Arthrospira platensis Species 0.000 claims 1
• 235000016425 Arthrospira platensis Nutrition 0.000 claims 1
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 229920000858 Cyclodextrin Polymers 0.000 claims 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
• RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 claims 1
• 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 claims 1
• LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
• 208000007914 Labor Pain Diseases 0.000 claims 1
• 208000035945 Labour pain Diseases 0.000 claims 1
• 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 claims 1
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
• 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
• 206010029279 Neurogenic bladder Diseases 0.000 claims 1
• YIRGBFIKWFVYMK-UHFFFAOYSA-N O=[ClH]=O Chemical compound O=[ClH]=O YIRGBFIKWFVYMK-UHFFFAOYSA-N 0.000 claims 1
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
• RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 claims 1
• NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 claims 1
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
• 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
• 206010039740 Screaming Diseases 0.000 claims 1
• 240000006394 Sorghum bicolor Species 0.000 claims 1
• 235000011684 Sorghum saccharatum Nutrition 0.000 claims 1
• 244000269722 Thea sinensis Species 0.000 claims 1
• CGCOVQSKNBEYNN-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]urea Chemical compound NC(=O)NC1=CC=C(C(F)(F)F)C=C1 CGCOVQSKNBEYNN-UHFFFAOYSA-N 0.000 claims 1
• LWYUUOZURSNBOH-UHFFFAOYSA-N [N+](=O)([O-])CCCCCCC=CC Chemical compound [N+](=O)([O-])CCCCCCC=CC LWYUUOZURSNBOH-UHFFFAOYSA-N 0.000 claims 1
• ROWKJAVDOGWPAT-UHFFFAOYSA-N acetyl methyl carbinol Natural products CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims 1
• 230000002378 acidificating effect Effects 0.000 claims 1
• 206010000496 acne Diseases 0.000 claims 1
• 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
• 230000036506 anxiety Effects 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
• 230000001746 atrial effect Effects 0.000 claims 1
• JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
• 150000001540 azides Chemical class 0.000 claims 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims 1
• CAKLQIFKPSEUFF-UHFFFAOYSA-N benzene 3H-dioxole Chemical compound C1OOC=C1.c1ccccc1 CAKLQIFKPSEUFF-UHFFFAOYSA-N 0.000 claims 1
• PDBLJVROGRYXEU-UHFFFAOYSA-N benzo[g][1,3]benzodioxole Chemical compound C1=CC=CC2=C(OCO3)C3=CC=C21 PDBLJVROGRYXEU-UHFFFAOYSA-N 0.000 claims 1
• FKQZODSYBFBADR-UHFFFAOYSA-N benzoic acid ethyl acetate Chemical compound CCOC(C)=O.OC(=O)c1ccccc1 FKQZODSYBFBADR-UHFFFAOYSA-N 0.000 claims 1
• 208000028683 bipolar I disease Diseases 0.000 claims 1
• 208000025307 bipolar depression Diseases 0.000 claims 1
• KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims 1
• 125000001589 carboacyl group Chemical group 0.000 claims 1
• HXFUVYFNBRBBPM-UHFFFAOYSA-N carpaine Natural products CC1(CCCCCCCC(=O)O1)C2CCCN2 HXFUVYFNBRBBPM-UHFFFAOYSA-N 0.000 claims 1
• 125000000068 chlorophenyl group Chemical group 0.000 claims 1
• 229910001916 chloryl Inorganic materials 0.000 claims 1
• 238000003776 cleavage reaction Methods 0.000 claims 1
• 230000000112 colonic effect Effects 0.000 claims 1
• 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
• RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 claims 1
• BSEXNZMHLUMQKR-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1.NC(=O)C1CC1 BSEXNZMHLUMQKR-UHFFFAOYSA-N 0.000 claims 1
• MJUJXFBTEFXVKU-UHFFFAOYSA-N diethyl phosphonate Chemical compound CCOP(=O)OCC MJUJXFBTEFXVKU-UHFFFAOYSA-N 0.000 claims 1
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
• 125000005594 diketone group Chemical group 0.000 claims 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
• 150000002013 dioxins Chemical group 0.000 claims 1
• 125000005879 dioxolanyl group Chemical group 0.000 claims 1
• 229910001882 dioxygen Inorganic materials 0.000 claims 1
• 150000002148 esters Chemical class 0.000 claims 1
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
• AZNWLXBPFLCADY-UHFFFAOYSA-N ethyl acetate ruthenium Chemical compound [Ru].C(C)(=O)OCC AZNWLXBPFLCADY-UHFFFAOYSA-N 0.000 claims 1
• 125000004494 ethyl ester group Chemical group 0.000 claims 1
• WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 claims 1
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims 1
• 125000004175 fluorobenzyl group Chemical group 0.000 claims 1
• 125000001207 fluorophenyl group Chemical group 0.000 claims 1
• JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims 1
• 210000004907 gland Anatomy 0.000 claims 1
• 231100000869 headache Toxicity 0.000 claims 1
• 235000003642 hunger Nutrition 0.000 claims 1
• 150000002431 hydrogen Chemical class 0.000 claims 1
• GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 claims 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims 1
• 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
• 229910052740 iodine Inorganic materials 0.000 claims 1
• 239000011630 iodine Substances 0.000 claims 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 1
• GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
• 229940095102 methyl benzoate Drugs 0.000 claims 1
• 150000004702 methyl esters Chemical class 0.000 claims 1
• JYXPWUYLZPYOAH-UHFFFAOYSA-N methylhydrazine Chemical compound CN=N JYXPWUYLZPYOAH-UHFFFAOYSA-N 0.000 claims 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
• 239000008267 milk Substances 0.000 claims 1
• 210000004080 milk Anatomy 0.000 claims 1
• 235000013336 milk Nutrition 0.000 claims 1
• 239000011707 mineral Substances 0.000 claims 1
• ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 1
• 206010028417 myasthenia gravis Diseases 0.000 claims 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims 1
• BJEYNNFDAPPGST-UHFFFAOYSA-N oxirene Chemical compound O1C=C1 BJEYNNFDAPPGST-UHFFFAOYSA-N 0.000 claims 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
• 230000001717 pathogenic effect Effects 0.000 claims 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
• ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 claims 1
• 208000020016 psychiatric disease Diseases 0.000 claims 1
• PNNRZXFUPQQZSO-UHFFFAOYSA-N pyran Chemical compound [CH]1OC=CC=C1 PNNRZXFUPQQZSO-UHFFFAOYSA-N 0.000 claims 1
• 125000001725 pyrenyl group Chemical group 0.000 claims 1
• 230000001698 pyrogenic effect Effects 0.000 claims 1
• 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims 1
• 208000023504 respiratory system disease Diseases 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 125000006413 ring segment Chemical group 0.000 claims 1
• 210000001991 scapula Anatomy 0.000 claims 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
• 201000000980 schizophrenia Diseases 0.000 claims 1
• 230000007017 scission Effects 0.000 claims 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
• 239000002689 soil Substances 0.000 claims 1
• 229940082787 spirulina Drugs 0.000 claims 1
• 229910052712 strontium Inorganic materials 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
• LWOLJZRFQMSDAZ-UHFFFAOYSA-N syn-benzene dioxide Chemical compound C1=CC2OC2C2OC21 LWOLJZRFQMSDAZ-UHFFFAOYSA-N 0.000 claims 1
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims 1
• 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 1
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
• 229920002554 vinyl polymer Polymers 0.000 claims 1
• 239000002585 base Substances 0.000 description 32
• 125000004432 carbon atom Chemical group C* 0.000 description 23
• 108091006146 Channels Proteins 0.000 description 21
• 230000000694 effects Effects 0.000 description 13
• 238000000034 method Methods 0.000 description 12
• 241000282414 Homo sapiens Species 0.000 description 10
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 10
• 241000282412 Homo Species 0.000 description 9
• 229940002612 prodrug Drugs 0.000 description 9
• 239000000651 prodrug Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 229940079593 drug Drugs 0.000 description 8
• 208000021722 neuropathic pain Diseases 0.000 description 8
• 125000001183 hydrocarbyl group Chemical group 0.000 description 7
• 239000002090 nanochannel Substances 0.000 description 7
• 239000003195 sodium channel blocking agent Substances 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 229940005483 opioid analgesics Drugs 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• RZVAJINKPMORJF-UHFFFAOYSA-N N-acetyl-para-amino-phenol Natural products CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 210000002683 foot Anatomy 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 210000001428 peripheral nervous system Anatomy 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 208000005298 acute pain Diseases 0.000 description 4
• 230000000202 analgesic effect Effects 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000004027 cell Anatomy 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• 239000003589 local anesthetic agent Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
• 239000011148 porous material Substances 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 229940125794 sodium channel blocker Drugs 0.000 description 4
• 229910052717 sulfur Chemical group 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 3
• 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229940035676 analgesics Drugs 0.000 description 3
• 239000001961 anticonvulsive agent Substances 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000009849 deactivation Effects 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000002651 drug therapy Methods 0.000 description 3
• 206010015037 epilepsy Diseases 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 208000020470 nervous system symptom Diseases 0.000 description 3
• 125000002971 oxazolyl group Chemical group 0.000 description 3
• 229960005489 paracetamol Drugs 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 230000035807 sensation Effects 0.000 description 3
• 235000019615 sensations Nutrition 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
• QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
• 206010000599 Acromegaly Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010059027 Brugada syndrome Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 240000006890 Erythroxylum coca Species 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
• 208000034972 Sudden Infant Death Diseases 0.000 description 2
• 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 229960000583 acetic acid Drugs 0.000 description 2
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
• 230000036982 action potential Effects 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003416 antiarrhythmic agent Substances 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 235000008957 cocaer Nutrition 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 229960002069 diamorphine Drugs 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 229960004194 lidocaine Drugs 0.000 description 2
• 229960005015 local anesthetics Drugs 0.000 description 2
• 230000028161 membrane depolarization Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• 229940127240 opiate Drugs 0.000 description 2
• 239000000014 opioid analgesic Substances 0.000 description 2
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
• 239000002831 pharmacologic agent Substances 0.000 description 2
• RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 150000004032 porphyrins Chemical class 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000006722 reduction reaction Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000001044 sensory neuron Anatomy 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• 210000003594 spinal ganglia Anatomy 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 125000005323 thioketone group Chemical group 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• BDURKQYFVDQCFR-GASJEMHNSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-sulfanyloxane-2,4,5-triol Chemical compound SC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO BDURKQYFVDQCFR-GASJEMHNSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• QMHRAPNTEVRWMG-UHFFFAOYSA-N 1,2,3-trimethyl-9h-fluorene Chemical group C12=CC=CC=C2CC2=C1C=C(C)C(C)=C2C QMHRAPNTEVRWMG-UHFFFAOYSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• DPTNMLUPFDKDAJ-UHFFFAOYSA-N 1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1 DPTNMLUPFDKDAJ-UHFFFAOYSA-N 0.000 description 1
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
• PTZIVVDMBCVSMR-UHFFFAOYSA-N 2,3-diphenylpyrazine Chemical compound C1=CC=CC=C1C1=NC=CN=C1C1=CC=CC=C1 PTZIVVDMBCVSMR-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• WSYAMLNOVPXLTR-UHFFFAOYSA-N 7,8-dioxabicyclo[4.2.0]octa-1,3,5-triene Chemical compound C1=CC=C2OOC2=C1 WSYAMLNOVPXLTR-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 244000144730 Amygdalus persica Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000011511 Diospyros Nutrition 0.000 description 1
• 241000723267 Diospyros Species 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 102000013138 Drug Receptors Human genes 0.000 description 1
• 108010065556 Drug Receptors Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 208000004454 Hyperalgesia Diseases 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• CJFYTVBNJIPEHT-UHFFFAOYSA-N N1N=CC=C1CCCCCCCCCN Chemical class N1N=CC=C1CCCCCCCCCN CJFYTVBNJIPEHT-UHFFFAOYSA-N 0.000 description 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 241000758706 Piperaceae Species 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010036772 Proctalgia Diseases 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
• 235000006040 Prunus persica var persica Nutrition 0.000 description 1
• ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• 206010040021 Sensory abnormalities Diseases 0.000 description 1
• 206010040738 Sinus arrest Diseases 0.000 description 1
• 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
• 101710134422 Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010085012 Steroid Receptors Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 235000009470 Theobroma cacao Nutrition 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 206010046788 Uterine haemorrhage Diseases 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 229960000250 adipic acid Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000005452 alkenyloxyalkyl group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003288 anthiarrhythmic effect Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 229960005261 aspartic acid Drugs 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 230000037424 autonomic function Effects 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 125000000477 aza group Chemical group 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 229960005286 carbaryl Drugs 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 239000004075 cariostatic agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000012084 conversion product Substances 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• CCZOANFFMASREE-UHFFFAOYSA-N cyclohexane;sulfamic acid Chemical compound NS(O)(=O)=O.C1CCCCC1 CCZOANFFMASREE-UHFFFAOYSA-N 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 210000003298 dental enamel Anatomy 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229960000632 dexamfetamine Drugs 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 125000000597 dioxinyl group Chemical group 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• PXJQUUBMKNTLHO-UHFFFAOYSA-N ethane;sulfane Chemical compound S.CC PXJQUUBMKNTLHO-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
• LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960005219 gentisic acid Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 210000000020 growth cone Anatomy 0.000 description 1
• DXTIKTAIYCJTII-UHFFFAOYSA-N guanidine acetate Chemical compound CC([O-])=O.NC([NH3+])=N DXTIKTAIYCJTII-UHFFFAOYSA-N 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 229940099563 lactobionic acid Drugs 0.000 description 1
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
• 229960001848 lamotrigine Drugs 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000010291 membrane polarization Effects 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 239000003612 morphinomimetic agent Substances 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000004412 neuroendocrine cell Anatomy 0.000 description 1
• 231100000878 neurological injury Toxicity 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 229940121367 non-opioid analgesics Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229960002969 oleic acid Drugs 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960005010 orotic acid Drugs 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229940124583 pain medication Drugs 0.000 description 1
• 230000008050 pain signaling Effects 0.000 description 1
• 229940124707 pain therapeutics Drugs 0.000 description 1
• 229940098695 palmitic acid Drugs 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 239000003016 pheromone Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 125000003386 piperidinyl group Chemical class 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 238000009258 post-therapy Methods 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 235000021251 pulses Nutrition 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 238000007142 ring opening reaction Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 210000001013 sinoatrial node Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000008925 spontaneous activity Effects 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 102000005969 steroid hormone receptors Human genes 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 229920001864 tannin Polymers 0.000 description 1
• 239000001648 tannin Substances 0.000 description 1
• 235000018553 tannin Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
• CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
• 229950010357 tetrodotoxin Drugs 0.000 description 1
• CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000004149 thio group Chemical group *S* 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000012384 transportation and delivery Methods 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
• 125000004385 trihaloalkyl group Chemical group 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 229940045136 urea Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1